Long-term renal survival of paediatric patients with lupus nephritis
- PMID: 33826705
- DOI: 10.1093/ndt/gfab152
Long-term renal survival of paediatric patients with lupus nephritis
Abstract
Background: Childhood-onset systemic lupus erythematosus (SLE) is more severe than adult-onset disease, including more frequent kidney involvement. This study aimed to investigate baseline clinical features, treatment modalities and short- and long-term renal outcomes of paediatric patients with lupus nephritis (LN).
Materials and methods: This study enrolled 53 LN patients out of 102 childhood-onset SLE patients followed at Hacettepe University between 2000 and 2020. The demographic and clinical data were reviewed retrospectively from the medical charts and electronic records. All SLE patients with renal involvement underwent renal biopsy either at the time of diagnosis or during follow-up.
Results: The median age at onset of SLE was 13.3 years [interquartile range (IQR) 10.4-15.8]. The median follow-up duration was 43.1 months (IQR 24.3-69.3). Of the 102 SLE patients, 53 (52%) had LN. The most frequent histopathological class was Class IV LN (54.7%), followed by Class III (22.6%). The proportion of patients who achieved either complete or partial remission was 77.3% and 73% at 6 and 12 months, respectively. In the overall LN cohort, 5- and 10-year renal survival rates were 92% and 85.7%, respectively. The remission rate at Month 6 was significantly higher in mycophenolate mofetil (MMF)- and cyclophosphamide (CYC)-treated groups than other combination therapies (P = 0.02). Although no difference was found between the CYC and MMF response rates (P = 0.57) in proliferative LN (Classes III and IV), the majority of Class IV patients (79%) received CYC as induction therapy. There was no difference between the response rates in any treatment regimens at Month 12 (P = 0.56). In the multivariate analysis, male gender, requiring dialysis at the time of LN diagnosis and failure to achieve remission at 6 and 12 months were found to be associated with poor renal outcome.
Conclusions: Our study demonstrated that male gender, failure to achieve remission at 6 and 12 months and requiring dialysis at the time of diagnosis were the best predictors of poor renal outcome. Therefore appropriate and aggressive management of paediatric LN is essential to achieve and maintain remission.
Keywords: childhood-onset systemic lupus erythematosus; cyclophosphamide; lupus nephritis; mycophenolate mofetil; renal outcome.
© The Author(s) 2021. Published by Oxford University Press on behalf of ERA-EDTA.
Similar articles
-
Long-term outcomes of lupus nephritis treated with regimens based on cyclophosphamide and mycophenolate mofetil.Lupus. 2020 Jul;29(8):845-853. doi: 10.1177/0961203320926256. Epub 2020 May 21. Lupus. 2020. PMID: 32437258
-
Outcome and predictors of renal survival in patients with lupus nephritis: Comparison between cyclophosphamide and mycophenolate mofetil.Int J Rheum Dis. 2018 May;21(5):1031-1039. doi: 10.1111/1756-185X.13274. Epub 2018 Apr 2. Int J Rheum Dis. 2018. PMID: 29611341
-
Remission and long-term outcomes of proliferative lupus nephritis: retrospective study of 96 patients from Saudi Arabia.Lupus. 2019 Aug;28(9):1082-1090. doi: 10.1177/0961203319860584. Epub 2019 Jul 11. Lupus. 2019. PMID: 31296138
-
Rituximab use as induction therapy for lupus nephritis: a systematic review.Lupus. 2020 Jul;29(8):892-912. doi: 10.1177/0961203320928412. Epub 2020 Jun 2. Lupus. 2020. PMID: 32486934
-
Comparative efficacy and safety of mycophenolate mofetil and cyclophosphamide in the induction treatment of lupus nephritis: A systematic review and meta-analysis.Medicine (Baltimore). 2020 Sep 18;99(38):e22328. doi: 10.1097/MD.0000000000022328. Medicine (Baltimore). 2020. PMID: 32957400 Free PMC article.
Cited by
-
Early-onset lupus nephritis.Clin Kidney J. 2024 Jul 13;17(8):sfae212. doi: 10.1093/ckj/sfae212. eCollection 2024 Aug. Clin Kidney J. 2024. PMID: 39135943 Free PMC article. Review.
-
Extrapolation of the Efficacy and Pharmacokinetics of Belimumab to Support its Use in Children with Lupus Nephritis.Clin Pharmacokinet. 2024 Sep;63(9):1313-1326. doi: 10.1007/s40262-024-01422-y. Epub 2024 Sep 25. Clin Pharmacokinet. 2024. PMID: 39320441 Free PMC article.
-
HDAC6 promotes inflammation in lupus nephritis mice by regulating transcription factors MAFF and KLF5 in renal fibrosis.Ren Fail. 2024 Dec;46(2):2415517. doi: 10.1080/0886022X.2024.2415517. Epub 2024 Oct 16. Ren Fail. 2024. PMID: 39412062 Free PMC article.
-
Developing a Label-Free Infrared Spectroscopic Analysis with Chemometrics and Computational Enhancement for Assessing Lupus Nephritis Activity.Biosensors (Basel). 2025 Jan 11;15(1):39. doi: 10.3390/bios15010039. Biosensors (Basel). 2025. PMID: 39852090 Free PMC article.
-
Lupus Nephritis in Children: Novel Perspectives.Medicina (Kaunas). 2023 Oct 16;59(10):1841. doi: 10.3390/medicina59101841. Medicina (Kaunas). 2023. PMID: 37893559 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical